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ABSTRACT
Objectives
ANCA-associated vasculitis (AAV) is considered a chronic, relapsing condition. To date, 
no studies have investigated multimorbidity in AAV nationally. Here, we characterise 
temporal trends in multimorbidity and report excess healthcare expenditure associated 
with it in a national AAV cohort. 
Methods
AAV patients diagnosed between 1997 and 2017 were matched with five general 
population controls. Linked morbidity and healthcare expenditure data were retrieved 
from a national hospitalisation repository and nationally-published cost data. 
Multimorbidity was defined as the development of ≥2 disorders. Pre-specified morbidities 
were analysed individually and together over time using modified Poisson regression, 
discrete interval analysis and Chi-squared test for trend. The relationship with healthcare 
expenditure was investigated using multivariate linear regression.
Results
543 AAV patients (58.7 [48.9-68.0] years; 53.6% male) and 2,672 controls (58.7 [48.9-
68.0] years; 53.7% male) were matched and followed-up for 5.1 years. AAV patients 
were more likely to develop individual morbidities at all timepoints, but especially <2 
years post-diagnosis. The highest proportional risk was observed for osteoporosis 
(adjusted incident rate ratio 8.0, 95% CI 4.5-14.2). After one year, 23.0% of AAV patients 
and 9.3% of controls were multimorbid (p<0.0001). After ten years, 37.0% of AAV 
patients and 17.3% of controls were multimorbid (p<0.0001). Multimorbidity was 
associated with disproportionate increases in healthcare expenditure in AAV patients. 
Healthcare expenditure was highest for AAV patients with ≥3 morbidities (3.89, 95% CI 
2.83-5.31; p <0.001 versus no morbidities). 
Conclusions
Our findings emphasise the importance of holistic care in AAV and identify a potentially 
critical opportunity to consider early screening.A
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INTRODUCTION
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a set 
of systemic autoimmune diseases, comprising granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis 
(EGPA).1 With modern immunosuppressive therapy, these previously fatal diseases have 
become chronic, relapsing conditions with mean five-year survival rates of ~70%.2
With improved survival, AAV patients are now at an increased risk of multimorbidity, 
defined as the presence of two or more concurrent long-term disorders.3 Multimorbidity is 
increasingly common in the general population4 and has also been described in other 
chronic inflammatory conditions including rheumatoid arthritis.5,6 It complicates chronic 
disease management and is associated with reduced functional status, decreased quality 
of life and increased mortality.7,8 Multimorbidity also has important implications for the 
organisation and delivery of healthcare, which is traditionally structured to optimise the 
management of individual diseases.9 
Previous studies have demonstrated an increased risk of several individual morbidities in 
AAV, including cardiovascular disease, diabetes mellitus and venous thromboembolic 
disease.10-13 These associations are thought to be a consequence of chronic 
inflammation or the increasingly potent and toxic medications used to treat AAV.14 
However, to our knowledge, no studies have yet investigated the frequency or burden of 
multimorbidity in AAV patients. In this national multi-centre data-linkage study, we 
compare temporal trends in the incidence of a wide range of individual morbidities and 
multimorbidity between AAV patients and matched general population controls, and 
report the cost of excess resource consumption attributable to multimorbidity in AAV 
patients.
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METHODS
Study design and data linkage
We performed a retrospective, matched-cohort population-based data-linkage study 
using routine healthcare data from multiple national registries (Supplementary Figure 
1). Record linkage was conducted by NHS Scotland using a robust methodology that has 
previously been shown to produce highly accurate and complete data.15,16
Study population
AAV patients were identified by clinicians using the European Medicines Agency criteria17 
in seven secondary and tertiary care hospitals across Scotland. Patients were eligible for 
inclusion if they were diagnosed with AAV after 1st January, 1995 and were aged 16 
years or older at the time of data-linkage. The date of AAV diagnosis was assigned as 
the index date. Each patient was matched with at least one, but up to five, general 
population controls based on age (±2 years), sex and postal (‘zip’) code of residence. 
General population controls were assigned the same index date as their matched AAV 
patient.
Study follow-up
Patients were followed-up from the index date until their date of death or 28th February 
2017, whichever came first. Information regarding cause of death was obtained via data 
linkage from the National Records of Scotland death registry, which records all deaths in 
Scotland.18
Definition and identification of individual morbidities and multimorbidity
Morbidities were defined as clinically distinct diseases co-occurring with AAV, but which 
were not a direct complication of AAV itself (e.g. chronic kidney disease, neuropathy, 
arthritis and sino-nasal disease). Our analysis focused a priori on a set of twelve 
individual morbidities of public health concern in elderly populations, which were 
identified following discussions between senior co-authors and an extensive review of the 
relevant multimorbidity literature (Supplementary Figure 1).19,20 The majority of these 
morbidities have previously been shown to be identifiable from administrative datasets 
with moderate to high validity.20 Multimorbidity was defined as the presence of two or A
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more disorders and was determined by summing each patient’s individual morbidities at 
specific timepoints (years 1, 2, 5 and 10). Information regarding each patient’s morbidities 
was obtained via data linkage with a national, population-based hospitalisation repository. 
This registry holds information on the discharge codes of all Scottish hospitalisations 
since the 1980s and details up to five diagnoses per admission.21 The first diagnosis 
corresponds to the primary reason for hospitalisation, whilst the remaining diagnoses 
capture information regarding the patient’s morbidities. All diagnostic codes recorded for 
each hospitalisation were included in this analysis.
Morbidities were identified using previously validated International Classification of 
Diseases (ICD) codes (ICD-9 pre-1996; ICD-10 post-1996) and are listed in 
Supplementary Table 1.20,22,23 The first date that a relevant diagnostic code appeared in 
a patient’s record was assigned as the incident date for that specific morbidity. Individual 
morbidities identified during the five years prior to the patient’s enrolment in the study (i.e. 
prior to the index date) were classified as pre-existing morbidities and were thus excluded 
from the analysis. This duration of ‘look-back’ period has previously been shown to allow 
the accurate determination of incident from prevalent morbidities when using routine 
healthcare data.24
Determination of healthcare expenditure
Count data regarding the number of outpatient encounters, inpatient hospitalisations and 
overall length of inpatient stay (on both general medical wards and intensive care units) 
were obtained via data-linkage with the Scottish outpatients and hospitalisations 
registries for each study year (Supplementary Figure 1). The NHS Scottish Health 
Service Costs Book was used to obtain annual tariffs for resource consumption.25 Tariffs 
were inflated to 2016 values using the Hospital and Community Health Service (HCHS) 
Index. Inaccessible data regarding tariffs from pre-2002 were estimated using the 2002 
tariff as the reference for deflation. 
Statistical analysis 
Baseline characteristics were summarised for AAV patients and matched general 
population controls. Incident morbidities were summed for each participant and used to A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
derive an ordinal variable representing patients with 0, 1, 2, or 3 or more morbidities. 
Differences in the proportions of AAV patients and general population controls in each of 
these categories were compared using the Chi-squared test for trend. 
The overall risk for individual morbidities in AAV and controls were compared using 
modified Poisson regression models, adjusted for age, sex, and local health board.26,27 
Discrete-time analysis was conducted with follow-up at 1, 2, 5 and 10 years using Lexis 
expansions.28 These timepoints were selected a priori based on current treatment 
guidelines on the duration of induction and remission therapy in AAV,29 in order to 
provide sufficient granularity to observe potential temporal changes in the occurrence of 
morbidities. The incidence rates for individual morbidities at each interval was calculated 
by dividing the number of morbidities observed in each interval by person-years of follow-
up included in each interval. Ninety-five percent confidence intervals (95% CIs) were 
computed using the Poisson assumption.30
A multivariate linear regression model, adjusted for age, sex and deprivation status 
(Appendix), was created to determine the relationship between number of individual 
morbidities and healthcare expenditure. As the residuals were not normally distributed, 
the continuous dependent variable ‘healthcare expenditure’ was log-transformed using 
the natural logarithm. Homoscedasticity was evaluated using the Breusch-Pagan test. All 
analyses were performed in Stata (version 14)31 and R (version 3.6.1).32 
Ethical considerations
This study was conducted in compliance with the Helsinki Declaration. Approval was 
received from the Scotland Research Ethics Committee A (Reference: 15-SS-0152). 
Individual patient consent was not required as the research was approved by the Public 
Benefit and Privacy Panel for Health and Social Care who oversee studies accessing 
anonymised healthcare data held by the NHS Scotland. Information governance, 
confidentiality and data protection were undertaken according to the Data Protection Act 
(1998). All study data were analyzed and held within a unique, secure national safe 
haven environment33 administered by the Electronic Data and Innovation Service 
(eDRIS), NHS Scotland.A
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RESULTS 
Five-hundred and forty-three AAV patients (median age at index 58.7 [48.9 to 68.0] 
years; 53.6% male) were matched with 2,672 general population controls (median age at 
index 58.7 [48.9 to 68.0] years; 53.7% male) and followed-up for a median of 5.1 [2.5 to 
9.4] years (Table 1). Three hundred and sixteen (58.2%) AAV patients had GPA, 157 
(28.9%) had MPA, and 68 (12.5%) had EGPA. PR3-ANCA was present in 52.7% 
(286/543) AAV patients and MPO-ANCA was present in 34.6% (188/543) AAV patients. 
A total of 12.0% (65/543) AAV patients were classified as ANCA negative.
Risk of developing individual morbidities in AAV
The risk of developing most individual morbidities was higher in AAV patients than in 
general population controls (Figure 1). The morbidity most frequently observed in AAV 
patients during study follow-up was hypertension (19.7% [92/466] in AAV patients versus 
9.4% [234/2,482] in general population controls; p<0.0001) (Table 2). However, the 
highest proportional risk difference between AAV patients and general population 
controls was observed for osteoporosis (adjusted incident rate ratio [IRR] 8.0, 95% CI 4.5 
- 14.2) (Figure 1). A sensitivity analysis exploring the proportional risk of hospital 
admissions due to hip fractures was performed to validate this finding. The risk of hip 
fractures in AAV patients was found to be twice that of general population controls 
(adjusted IRR 2.0, 95% CI 1.1 - 3.7). To explore the influence of surveillance bias, a 
further sensitivity analysis was performed to evaluate the proportional risk of 
hypothyroidism and stroke in only those patients and controls with a record of at least 
one hospitalisation during study follow-up (Supplementary Results).
Temporal trends in individual morbidities and multimorbidity in AAV
Figure 2 illustrates trends in the incidence of individual morbidities over time following 
AAV diagnosis. In general, the highest incidence for most morbidities was observed 
during the first two years of follow-up. This was especially marked for hypertension and 
hypothyroidism. However, a further increase in the incidence of several morbidities, 
including cardiovascular disease, diabetes mellitus and chronic pulmonary disease, was 
also noted from five to ten years after AAV diagnosis. A
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The proportion of study participants developing at least one incident morbidity increased 
over time in both AAV patients and general population controls (Figure 3). However, at 
every timepoint, AAV patients developed a significantly higher number of individual 
morbidities than general population controls (Figure 3; p<0.0001 for all timepoints). 
Multimorbidity (defined as the presence of two or more disorders) was also more 
common in AAV patients than general population controls at all timepoints. For example, 
after one year of follow-up, 23.0% (125/543) of AAV patients could be considered 
multimorbid versus 9.3% (248/2,672) of general population controls (p<0.0001). Ten 
years after diagnosis, a further 37.0% (101/273) of AAV patients had developed 
multimorbidity, compared with 17.3% (235/1,362) of general population controls 
(p<0.0001). 
Healthcare expenditure attributable to multimorbidity in AAV patients
Figure 4 illustrates the relationship between number of individual incident morbidities and 
the total cost of excess resource consumption due to outpatient encounters and inpatient 
hospitalisations (to both general medical wards and intensive care units) in 502 AAV 
patients during study follow-up. Multivariate linear regression modelling confirmed that 
the development of multimorbidity was associated with a proportionally higher cost of 
excess resource consumption in AAV patients (Supplementary Table 2). Compared to 
the development of no morbidities during study follow-up, the development of two 
morbidities was associated with a 2.78-fold (95% CI 2.09 - 3.71; p<0.0001) increase in 
healthcare expenditure in AAV patients, whilst the development of three or more 
morbidities was associated with a 3.89-fold (95% CI 2.83 - 5.31; p<0.001) increase in 
healthcare expenditure in AAV patients. The increases in total healthcare expenditure 
observed with the development of multimorbidity are predominantly related to increases 
in inpatient, rather than outpatient, healthcare expenditure (Supplementary Results; 
Supplementary Tables 3 and 4).
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DISCUSSION
This is the first study to describe longitudinal trends in the incidence of multimorbidity and 
report the healthcare expenditure attributable to multimorbidity in a large, national cohort 
of AAV patients. We report a number of important observations. First, AAV patients are at 
a significant risk of developing individual morbidities throughout their disease course, but 
especially in the first two years following diagnosis. Second, multimorbidity (the presence 
of two or more disorders) is common in AAV patients and increases significantly in 
frequency over time. Indeed, it affected almost one-quarter of AAV patients in their first 
year after diagnosis, but over one-third by year ten of follow-up. Third, multimorbidity is 
associated with an approximately three-fold increase in excess healthcare expenditure in 
AAV patients.
Uniquely, our study demonstrates that AAV patients are at an increased risk of 
developing multimorbidity compared to general population controls. Whilst the impact of 
multimorbidity has not been studied previously in AAV, we also found that multimorbidity 
is associated with a disproportionate increase in the cost of overall excess resource 
consumption. In comparison to AAV patients with no morbidities, the development of 
multimorbidity in AAV patients is associated with a two- to four-fold increase in total 
healthcare expenditure, but a three- to five-fold increase in inpatient healthcare 
expenditure. Relevant studies in other chronic disease populations, for example in 
patients with cardiovascular34 or chronic kidney disease35 have also demonstrated that 
multimorbidity is becoming the rule rather than the exception.9,36 The implications of this 
are significant, given the striking association of multimorbidity with polypharmacy, greater 
resource consumption, reduced quality of life and poorer outcomes.7-9,37 
Our findings are also consistent with previous assessments of individual morbidities in 
AAV. In relation to the risk of cardiovascular disease, we demonstrate an increased risk 
in both early and late stages of AAV.10,11,38 Uniquely, our study extends these findings to 
other cardiovascular disorders including valvular disease and arrhythmias, both of which 
demonstrate a similar bimodal risk pattern over time. Although primary cardiovascular 
disease is relatively uncommon in AAV, the observed risk may be due to a combination 
of chronic inflammation and corticosteroid toxicity.39,40 It is possible that these findings A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
are partly explained by surveillance bias. For example, valvular heart disease may have 
been diagnosed during routine echocardiography, which AAV patients are more likely to 
undergo than general population controls. 
As general population controls were not selected from the timepoint of a new diagnosis, 
the increased risk observed for several morbidities early in the AAV disease course may 
also be explained by surveillance bias due to the additional investigations performed in 
AAV patients following their index diagnosis. For example, AAV patients are commonly 
tested for hypothyroidism as part of their diagnostic work-up. Nevertheless, an increased 
risk of hypothyroidism has previously been demonstrated in AAV patients prior to 
diagnosis, which aligns with accumulating evidence supporting shared mechanisms 
across the autoimmune disease spectrum.41 Similarly, the increased risk of osteoporosis 
in AAV patients observed in the present study may be related to current guideline 
recommendations for dual energy x-ray absorptiometry (DEXA) scans when patients 
commence corticosteroids.29 Hip fractures are a reliable surrogate end-point unlikely to 
be affected by surveillance bias and as a result we performed a sensitivity analysis to 
evaluate the risk of hip fractures during follow-up. Interestingly, we observed that the risk 
of hip fractures in AAV patients was twice that of general population controls - verifying 
our finding that osteoporosis risk is indeed increased in AAV patients.
Our findings have important implications for clinical practice. Specifically, the results of 
our temporal analysis highlight the importance of early screening for many common 
conditions in AAV patients, whilst also highlighting the significance of late-onset 
cardiovascular disease and diabetes mellitus. Our observation that peptic ulcer disease is 
no more likely in AAV patients than general population controls, despite the 
administration of high-dose corticosteroids to the former group, also appears to reflect the 
relative success of prophylactic therapies aimed at suppressing gastric acid secretion. 
Therefore, our data encourage similar preventative strategies for other morbidities.  
Further research is required to understand what exact mechanisms underlie the 
increased risk of multimorbidity we observed in AAV patients. Given the relationship 
between multimorbidity and adverse pharmacological effects, such work could ultimately A
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incentivise a shift towards a reduction in the use of pharmacological therapies associated 
with numerous adverse effects, such as corticosteroids. Indeed, with the transformation 
of AAV into a chronic disease, it is timely to prioritise a more holistic approach towards 
the management of AAV patients. This is analogous to the concept of ‘cancer 
survivorship’, which has been established in oncology in response to improvements in 
cancer-related mortality. The overarching aim of cancer survivorship is to address the 
physical, psychological and social health burden that arises as a consequence of cancer 
patients living for longer.42 Clinicians must therefore consider how best to organise and 
deliver healthcare to AAV patients, in order to fully address both their multimorbidity and 
their primary disease. Greater collaboration with primary care providers is likely be critical 
to the potential success of any such move towards a more holistic approach to patient 
care in AAV.
Our study has several important strengths. Utilising one of the largest cohorts of AAV 
patients, we adopted a comprehensive approach for improving our understanding of the 
burden associated with multimorbidity in AAV patients. Indeed, our method for identifying 
AAV patients suitable for inclusion in our cohort was also robust. We also assessed 
prevalent morbidity burden using a validated length of ‘look-back’ period24 and previously-
verified ICD discharge coding,20,22,23 which has a reported accuracy of ~96% for common 
diagnoses recorded in SMR01.43  
However, a number of limitations must be considered. First, our study identified 
morbidities from secondary care records, which mostly capture major disorders. Despite 
including all available diagnostic codes, relatively minor disorders may have been 
overlooked by secondary care coders and so our incidence estimates are likely to be 
conservative. However, this will have affected AAV patients and general population 
controls equally. Second, given the higher hospitalisation rate observed in AAV patients 
(98% versus 79%), the incidence rate ratios for conditions managed in primary care are 
likely to be over-estimates. To address this limitation, we performed a sensitivity analysis 
including only those patients and controls with a hospitalisation record and found that the 
degree of over-estimate was small for hypothyroidism, stroke and myocardial infarction 
(see Appendix). Third, patients not hospitalized in the five years prior to their index date A
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were classified as having no pre-existing morbidities. It is therefore difficult to be certain 
exactly when these patients developed ‘incident’ morbidities. To limit the impact of this, 
we employed a validated24 fixed five year look-back period to standardize the 
identification of baseline morbidities across all patients. Fourth, study follow-up was 
limited to a median of five years, which may partly explain why we failed to demonstrate 
an increased risk of depression or dementia in AAV patients. Although sufficient for 
identifying relatively acute-onset conditions, longer follow-up is required to reliably 
establish the occurrence of more gradual-onset disorders, such as depression and 
dementia. Fifth, despite being one of the largest studies of its kind, we were unable to 
undertake stratified analysis by AAV type due to a lack of statistical power.
In conclusion, this novel study is the most comprehensive and detailed analysis of 
multimorbidity in AAV patients to date. AAV patients are at a high risk of individual 
morbidities, especially early in their disease course. Multimorbidity is also common in 
AAV patients and is associated with disproportionate increases in healthcare 
expenditure. Our findings emphasise the importance of holistic care in AAV patients and 
the need to consider early screening for other conditions.
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TABLES 
Table 1. Baseline characteristics of AAV patients and general population controls. 
AAV patients
General population 
controls
Number of participants, n 543 2,672
Male sex, n (%) 291 (53.6) 1434 (53.7)
Median age at index, years (IQR) 58.7 [48.9, 68.0] 58.7 [48.9, 68.0]
Follow-up, years (median; IQR) 5.1 [2.5, 9.4] 5.2 [2.5, 9.5]
AAV type, n (%)
GPA
MPA
EGPA
Missing
316 (58.2)
157 (28.9)
68 (12.5)
2 (0.4)
N/A
ANCA seropositivity, n (%)
PR3-ANCA
MPO-ANCA
ANCA negative
Missing
286 (52.7)
188 (34.6)
65 (12.0)
4 (0.7)
N/A
AAV: ANCA-associated vasculitis; GPA: Granulomatosis with Polyangiitis; MPA: 
Microscopic Polyangiitis; EGPA: Eosinophilic Granulomatosis with Polyangiitis; ANCA: 
Anti-Neutrophil Cytoplasmic-Antibody, PR3: Proteinase 3; MPO: Myeloperoxidase; NA: 
Not applicable.
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Table 2. Comparison of incident morbidities between AAV patients and general 
population controls during follow-up. Abbreviations: AAV – ANCA-associated vasculitis. 
*A full list of conditions encompassed by this term is provided in the Appendix.
AAV patients, n (%)
General population 
controls, n (%)
p-value
Cardiac arrhythmias 49 (9.6) 119 (5.0) <0.0001
Cardiovascular 
disease
61 (12.6) 236 (9.5) 0.042
Chronic pulmonary 
disease
46 (9.7) 120 (4.7) <0.0001
Depression <5 (<0.9) 21 (0.8) 0.749
Diabetes mellitus 37 (7.2) 94 (3.6) <0.0001
Dementia 6 (1.1) 32 (1.2) 0.846
Hypertension 92 (19.7) 234 (9.4) <0.0001
Hypothyroidism 21 (4.0) 34 (1.3) <0.0001
Osteoporosis 29 (5.4) 22 (0.8) <0.0001
Peptic ulcer disease <5 (<0.9) 21 (0.8) 0.918
Pulmonary circulation 
disorders*
31 (5.8) 30 (1.1) <0.0001
Valvular disease 46 (8.7) 80 (3.0) <0.0001
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FIGURE LEGENDS
Figure 1. Comparison of the incidence of individual morbidities in AAV patients with 
general population controls shown as incidence rate ratios (IRRs). IRRs were adjusted 
for age, sex, and local health board. The rate of incident morbidity in the general 
population controls was set as the reference. AAV: anti-neutrophil cytoplasmic antibody-
associated vasculitis; 95% CI: 95% confidence interval.
Figure 2. Temporal trends in the incidence of individual morbidities in AAV patients (red) 
and general population controls (blue). AAV: anti-neutrophil cytoplasmic antibody-
associated vasculitis. Scale of y-axis is different for hypertension.
Figure 3. Prevalence of morbidities at baseline and cumulative incidence of morbidities 
and multimorbidity at 1, 2, 5 and 10 years in AAV patients and general population 
controls. AAV: anti-neutrophil cytoplasmic antibody-associated vasculitis. P for χ2 test for 
trend <0.0001 for all timepoints. AAV: anti-neutrophil cytoplasmic antibody-associated 
vasculitis.
Figure 4. Alluvial plot illustrating the relationship between number of incident morbidities 
and total excess healthcare expenditure during study follow-up in AAV patients (n=502). 
AAV: anti-neutrophil cytoplasmic antibody-associated vasculitis. 
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